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Abstract 
The increasing threat inherent to counterfeited drugs requires coordinated effort among 
multiple actors with diverging interests. Although multiple initiatives exist, no 
comprehensive and promising development and diffusion of a commonly applicable and 
interoperable solution has taken place so far. Agreeing on standards is an essential step 
on the road to a successful initiative on drug counterfeiting. To facilitate standardization, 
especially the initiation of a standardization process, we propose the concept of Living 
Labs as an innovative developing and testing environment serving multiple purposes. 
Testing solutions in real-life-contexts, aligning multiple interests and resulting in a pre-
standard and a proof-of-concept are the advantages of this concept which facilitate the 
participation and coordinated action among a broad set of different stakeholders. 
 
Keywords: Collective Action, Living Labs, Standardization 
1 Introduction 
The infiltration of counterfeited pharmaceuticals into the pharmaceutical supply chain is 
an increasing, international problem, in developing countries but also increasingly in 
developed countries. The large volumes for pharmaceuticals, high margins for 
counterfeited drugs and the low penalties in conjunction with low risk of detection 
resemble an appealing field of activity for criminal minds. 
Whereas a large number of anti-counterfeiting initiatives account for the 
acknowledgement of the problem among industry members, governmental agencies, and 
patient associations (OECD, 2007a), most of these initiatives focus on particular 
solutions: Technology for enabling tracking and tracing, new packaging materials, 
regulation for good manufacturing practices etc. The international cross-linking of the 
pharmaceutical supply-chain, including multiple manufacturing phases across different 
countries, cross-boundary trade of ingredients, semi-finished and packaged drugs, 
emphasizes the need for a coordinated action among multiple stakeholders to face and 
limit this problem sustainable. In light of this threat and the number of existing 
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initiatives, the question can be raised, why no coordinated and transparency increasing 
system has been established?  
The example of developing and testing technical standards for this purpose is used in this 
paper to propose a research design that may facilitate this kind of collective action among 
multiple stakeholders.1 Interoperability with legacy systems of the stakeholders as well as 
the integration into different regulative environments pose challenges for the prospective 
technology enabled anticounterfeiting systems. 
By drawing on standardization process models in the literature and identified 
requirements we theorize that the concept of “Living Labs” can be used as an enabler of 
collective action, establishing an environment among a group of core stakeholders to 
identify and test pilot systems in real-life scenarios. Our argumentation is based on the 
literature and experiences from current research projects in the pharmaceutical industry.  
In the next section of this paper we will introduce the threat of counterfeited 
pharmaceuticals as well as characteristics of current anti-counterfeiting initiatives to the 
reader. Furthermore we motivate the need for standards as prerequisites for increasing 
transparency in the supply chain. In the third section we propose to conceive standard 
development as a threefold problem of collective action and Living Labs as a possible 
enabler of Collective action. In the last section we will discuss whether a Living Lab can 
serve as an incubator of collective action or not. This is followed by a brief conclusion. 
2 Facing counterfeiting of pharmaceuticals 
In this section we will introduce the reader to the increasing threat of counterfeited  
drugs. A large number of initiatives on different national and international  
levels, including governmental, intergovernmental, nongovernmental and private 
stakeholders were established in the recent years. We will provide some propositions 
about challenges faced by these initiatives that may explain the lack of observable 
improvements in terms of secure pharmaceuticals.  
2.1 Counterfeited drugs an increasing problem 
Counterfeiting in general is an increasing problem concerning almost all consumer 
goods. (OECD, 1998) In addition to the economic impact and the infringement of 
intellectual property rights, counterfeit pharmaceuticals2 pose severe dangers for human 
health or patient safety.  
Potential counterfeits could harm the pharmaceutical supply-chain at multiple levels, 
starting with the active ingredient over the finished pharmaceutical product and the 
packaging. These levels also comprise the shipment and distribution activities. (OECD, 
2007b) Figures according to the WHO state that 10% of the overall pharmaceuticals sold 
were faked, ranging up 30% in the developing countries with a total volume of U$ 75 
billion globally. (WHO, 2006-11-14)  
                                                          
1 In order to ensure the integrity of the whole supply chain we argue that a set of standards has to be 
developed that may be used to set up a trackingtracing system (TTS) on an interorganizational level. In 
this sense we conceive standards as multilateral agreements to ensure technical, organizational and 
procedural interoperability and compatibility. 
2 The Word Health Organization defines counterfeited pharmaceuticals as follows: “A product that is 
deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeiting can 
apply to both branded and generic products and counterfeit medicines may include products with the 
correct ingredients but fake packaging, with the wrong ingredients, without active ingredients or with 
insufficient active ingredients.” WHO, 2006-11-14 
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Several factors can be identified that facilitate the market entry of counterfeit medicines, 
e.g. in Europe (Harper & Bertrand, 2006). As a result of the single EU market can 
products that have illicitly entered one member state easily be disseminated throughout 
the entire EU. In this regard the practice of parallel trade and re-import further aggravates 
the complexity of the pharmaceutical supply chain. After being granted the authorization 
by any EU national regulatory authority pharmaceutical distributors may import any drug 
from any other member country to capitalize e.g. on substantial price differences among 
different countries. Furthermore several member states (e.g. Germany, Netherlands, 
Norway, Sweden, UK) stimulate dispensing of parallel imported pharmaceuticals in order 
to reduce ever increasing healthcare costs (Kanavos et al., 2005). In UK the parallel 
import accounted for 20 percent of total brand name prescription drug sales in 2002 
(Kanavos et al., 2005). 
2.2 Challenges for anti-counterfeiting initiatives 
The primary goal of measures to tackle counterfeited pharmaceuticals is to ensure 
integrity of the package, meaning for the patient to receive the unaltered medicine from 
the manufactures. In this regard “securing the supply chain” means that at least the point-
of-sale (pharmacy) can verify that the medicine or package is uncorrupted. This however 
implies that both manufacturer and pharmacy have to collaborate and agree on 
verification technologies and standards. 
The different regulations have a strong impact on a coordinated effort of standardization 
as well. The market for pharmaceuticals and their distribution is highly regulated 
throughout the EU. While at the same time the free movement of goods is proclaimed 
and legally enforced, slightly different legal frameworks can be observed in the EU. 
These differences among particular regulations are also barriers for standardization 
efforts, which should (especially) incorporate cross-boundary trade. 
Lack of market incentives for the particular players might therefore impede coordinated 
action amongst them. Neither the manufactures, nor wholesalers or pharmacies have a 
strong incentive or position to enable a coordinated action, which affects even 
international regulation. 
Manufacturers for example might have an economic interest. But they might face the 
dilemma of loss of reputation, when they prominently start action against the 
counterfeiting threat (e.g. might the patients assume, that especially the drugs of this 
manufacturer are counterfeited) having no solution at hand (because they just starting the 
effort). Also other stages of the pharmaceutical supply chain (wholesale, retail) lack 
either of power, economic incentives or both to implement more security in the supply 
chain.  
Governmental action can be assumed to overcome at least the lack of economic 
incentives forcing the market actors to comply. Although protection of public health is 
deemed to be a sovereign task such action is still missing. Various factors contribute to 
this lack of governmental action. Rising mistrust by patients in politicians announcing the 
requirement of a system (but at the same time having no system, not even a proof-of-
concept in sight) might impede here the government to tackle this issue prominently. 
Missing detailed and industry specific knowledge, the challenge of aligning national and 
international interests, and solving the problem of internationally distributed supply 
chains might be additional reasons for the absence of governmental action. 
In the previous paragraphs we have shown that neither the market nor the government 
alone can provide the necessary standards and proof-of-concept to establish a viable 
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solution. We conclude that a multi-stakeholder approach is needed to overcome the 
individual rationalities that prevent the sufficient provision of the public good “patient 
safety”.  
A large number of initiatives on different national and international level, including 
governmental, intergovernmental, non-governmental and private stakeholders (for a 
detailed overview of initiatives see OECD, 2007a) have been established. They tackle a 
broad range of issues, regarding technological, organizational and also regulatory issues. 
Missing efforts to coordinate the single parts into common and comprehensive 
approaches prevent them from being successful and sustainable for a broad set of 
contexts. 
The following table highlights potential shortcomings of existing initiatives or reasons of 
failure from the perspective of the particular driving party: 
 
 
 
Although most people in the pharmaceutical distribution industry acknowledge the 
potential threat of counterfeited pharmaceuticals there is no industry-wide nor 
international consensus that this relates to the own business or industry. As we have 
shown the economic incentives will not lead industry-wide applicable solutions in the 
near future. It has become clear that to overcome the threat of counterfeited 
pharmaceuticals only a multi-stakeholder approach is feasible. Precedence in other 
industries (e.g. beef) has shown that such approaches are gaining momentum after the 
crisis broke out (e.g. BSE and CJD). Based on this unsatisfactorily observation the next 
chapter introduces the theoretical grounding for our suggested research design which may 
lead to feasible solutions before a crisis breaks out. Facing the problem of enabling a 
standardization process, we illustrate the phases of standardization and the 
required collective action. By presenting the concept of Living Labs and applying it in 
our context we believe that it is possible to overcome or lower some of the barriers to 
coordinated action presented previously. 
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3 Theoretical Concepts 
We want to conceive the formation of such a system as a problem of collective action 
which would be needed for the development and consequent diffusion of a system. We 
interpret this as a problem of standard development and distinguish several phases in 
which actors have to assume different roles. 
3.1 Phases of Standardization and Collective Action 
In the previous sections we pointed out that standards are needed to ensure a close 
cooperation between the actors along the supply chain and relevant governmental 
agencies. By conforming to these standards the actors would be able to establish a 
pharmaceutical security trade chain involving different stages of the supply chain from 
different sectors and from different countries. The standards put forward here exhibit the 
characteristics of collective goods (non-excludability, non-rivalry). Hence, Collective 
Action Theory or Public Choice Theory seems a promising analytical viewpoint. 
Markus et al. have studied the consequences that collective good characteristics have on 
the development and diffusion process of standards. (Markus et al., 2006) By studying 
vertical information system standards they explored the linkage and differences between 
development and diffusion of standards as two distinct dilemmas. They come to the 
conclusion that for a successful standardization both need to be solved and addressed at 
the same time. 
The development of a standard requires a close coordination of the actors. Farrell & 
Saloner (1988) discuss three mechanisms to achieve coordination in regard to 
compatibility standards. In this paper we want to focus on the first, which deals with 
standardization committees in which negotiations take place before unilateral irrevocable 
choices are made. 
Before multilateral negotiations in such a context can take place the actors have to be 
persuaded to join the consortium. Reimers and Li argue for a transaction cost perspective 
to understand the individual firms‟ decision to join in (Reimers & Li, 2005). Following 
their argument each firm has to evaluate the costs of multilateral negotiations in a 
consortium and the costs it would incur by bilaterally negotiating with its business 
partners. In this model the costs depend largely on the number of competitors and 
intensity of competition among them. If several competing initiatives try to develop 
standard candidates uncertainty increases. This in return increases transaction costs. 
Therefore firms may prefer bilateral arrangements or simply adopt a free-rider position. 
This leads to two problems: First, no initiative will take off because of the free-rider 
problem. Second, the negotiating consortium might be too small to start a bandwagon 
effect in the diffusion phase. 
The dilemma of standard development is concerned with success and failure of a standard 
negotiation process. By drawing on Reimers and Li we theorize that an explanation why 
the negotiation process started at all is needed in the first place. 
Following Reimers and Li we distinguish between three phases instandardization 
processes (see Table 1): First, during the initiation phase the standard development 
consortium is formed. A nucleus of actors or at least one actor has to take the role of the 
initiative pusher by promoting or facilitating the formation of a forum to negotiate on 
standards. The outcome is a relatively stable consortium of actors that are willing to 
participate in the negotiation about a standard candidate. The standard is regarded as a 
“candidate” as it may or may not emerge as a de-facto standard in the third phase. In 
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Table 2 the phases of an abstract, consortium-driven standardization process and their 
outcomes are listed. 
 
 
 
Despite its importance the initiation phase is rather disregarded by the literature on 
standardization. We therefore want to elaborate further on the challenges of the initiation 
phase. 
As already pointed out the initiation phase is concerned with actors assuming two roles: 
the initiator and (passive) participants. One or more actors need to assume the role of an 
initiator (irrespective of their number hereby called initiator). 
During the initiation phase the initiator tries to identify and persuade the relevant actors 
that need to participate in the consortium. The initiator may be motivated intrinsically 
(e.g. economic incentives), by an exogenous event (e.g. a crisis) or it may be part of a 
mission that has been entrusted to the initiator. In order to persuade actors to join the 
consortium the initiator employs means that rely on resources at disposal of the initiator. 
The persuasion of an actor has to be seen as a negotiation process in which the interests 
between the actor and the initiator are aligned. 
Alignment means that both parties need to agree on the rules that will govern the 
consortium. Although they might have a diverging interest in the outcome of the 
activities of the consortium they need to find a common ground where their expectations 
are satisfied. In this regard the consortium needs to be interpretative flexible in order to 
accommodate the diverging interests. At this stage the addressed actor needs to evaluate 
the offer to participate in consortium. Despite a calculation of the (economic) costs and 
benefits to participate or not in this consortium the actors will evaluate the initiator and 
the other participants in terms of credibility, trustworthiness and past experiences. 
During the standard development phase the decision making process exhibits several 
potential areas of conflict between the parties. These are conflicts of interest, conflicts of 
alignment and conflicts of appropriation. (Müller-Tengelmann, 1995) Conflicts of 
interest refer to the heterogeneity of interests among the actors. For example some might 
have preferred to develop a proprietary standard in order to lock-in their customers or 
shut-out competitors. Another reason for supporting particular standard might be the 
existing intra-organizational infrastructure (internal lock-in). This leads to the conflicts of 
alignment. The conflicts of appropriation result from different cost/ benefit structures of 
the actors. And even in case of a negative cost/benefit ratio, actors might still favor the 
standard development.3 
                                                          
3
 Müller-Tengelmann mentions three situations that would explain such behaviour. First there might be 
dependencies among the actors that force some of them to be compliant to the requirements of their 
(business) partner. Second the investment is justified by future expectations to sustain and strengthen 
the business relationship. Alternatively costs can be passed on to a third party like customers or 
suppliers (Müller-Tengelmann, 1995). 
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After the standard candidate is developed the actors in the market have the choice to 
adopt the standard (if it has not become a de-jure standard). Due to network effects actors 
have the incentive to delay their adoption in order to wait until a critical mass has been 
reached. Additionally dependencies and asymmetric power structures can also force or 
impede actors to adopt a standard. Intellectual property rights at non-open standards, 
missing practicability or incompleteness are further factors influencing the adoption and 
diffusion process. 
This section demonstrates that a standardization process is precarious and characterized 
by a multiplicity of conflicts which have to be contained. The question arises how to set-
up an environment that provides promising surrounding conditions for a successful 
initiation of a standardization process. We will elaborate on this question in the next 
section by analyzing Living Labs as providing such an appropriate environment.  
3.2 Living Labs an appropriate incubator for CA? 
“Living Labs are collaborations of public-private partnerships in which stakeholders co-
create new products, services, businesses and technologies in real life environments and 
virtual networks in multi-contextual spheres.”(Feuerstein et al., 2008) 
This very broad definition of Living Labs is one indication for the typical characteristic 
of this construct. There co-exist multiple, not necessarily mutual exclusive 
understandings of what the concept “Living Lab” encompasses and how it could be 
utilized in practice.4 For example, Mulder et al. (2008) emphasize the „Living‟ part of the 
Living Lab. The integration and central meaning of the user in the research and design 
process in a real life-context facilitates the inclusion of experiences and dynamics among 
the technology, user and the social everyday context. 
In addition to this conceptual work on Living Labs, empirical analyses of existing Living 
Labs in Europe show some common characteristics among this type of collaboration 
environment. They typically focus on the creation of innovative services featuring ICT 
and involve stakeholders both from the public and private domain. (Shamsi, 2008) In 
addition to governmental and commercial stakeholders, academia is another typical 
stakeholder in the a Living Lab. (Almirall & Wareham, 2008) 
Based on the definition by Feuerstein (2008) and Almirall (2008) and the empirical 
findings from Shamsi (2008), we want to present our understanding of Living Labs in the 
context of multi-national and multi-stakeholder research projects. In contrast to Mulder et 
al. (2008), we focus not on the development of end-user technologies like ADSL or 
mobile applications, but analyze the issue of establishing standardization activities 
among a broad set of stakeholders with particular perspectives, interests and incentives. 
Especially in the context of standards development, the preservation of stakeholders‟ 
interests is seen as one opportunity to involve and endure the collaboration of industry 
members (David & Greenstein, 1990). 
                                                          
4 e.g. being it “a research methodology for sensing, prototyping, validating and refining complex 
solutions in multiple and evolving real life contexts” [Prof. William Mitchell, MIT Boston; taken from 
http://www.sricbi. com/LoD/meetings/2005-06-08/VPNiitamo.ppt] and similar usage in Souminen, 
2005, “an experimentation environment in which technology is given shape in real life contexts and in 
which (end) users are considered as ‚co-producers„“ Pierson, Lievens & Ballon, 2005, or a test 
environment for different technologies and competing business models Niitamo, Kulkki & Hribernik, 
2006. 
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Therefore we propose the concept of Living Labs being a research environment, bringing 
together a core group of stakeholders to explore potential solutions for a common 
problem and with each party having particular perspectives and interests. 
As mentioned before, one stakeholder, not necessarily involved in typical  
Public-Private-Partnerships, is academia. Being an active part of a Living Lab, academia 
can at least compensate some of the shortcomings inherent to initiatives driven mainly by 
stakeholders from the public or private domain (as presented in Table 1). Being neutral 
(in terms of economic interest) and unbiased (e.g. in terms of usage of a specific 
technology) upfront and relying on scientific and theoretical knowledge, the credibility of 
the university might be used to moderate and design a Living Lab. 
The outcome is not only the presentation of a proof-of-concept, but also the formulation 
of recommendations (in terms of legislation or organizational changes) and an 
assessment of impact (e.g. in terms of economic impact) for the stakeholders of this real-
life case. (Shamsi, 2008) Hence, the Living Lab could serve not only as a technological 
testing environment, but also to evaluate future obstacles to a wider diffusion and 
adoption. Based on the barriers to standardization and collective action activities and also 
based on the very broad definition and current understanding of Living Labs presented in 
the paragraphs before, we propose for our context four stages of designing and running a 
Living Lab: 
1. Funding and initiation 
Related to a concrete or upcoming challenge, a governmental or 
intergovernmental institution creates the opportunity to establish a Living Lab. 
This first stage mainly aims to reduce the barriers (both financial and political 
barriers) for the particular stakeholders to join this kind of research and 
development projects. 
2. Design and set-up 
Due to the complexity of the problem, the concrete design and set-up of the 
Living Lab could be done by an academic institution. Academia has multiple 
advantages in contrast to political or commercial parties. It could be assumed, that 
they are able to act neutrally, not being driven by financial or political interests 
and therefore being creditable. Also their theoretical funding sustains their 
credibility. 
Typical tasks are defining and detailing the description of the problem, 
considering potential technological solutions, establishing a network of 
stakeholders (being it technology providers and users of the technology) and also 
defining (in collaboration with the stakeholders) the outline of the following 
phase. 
3. Test, assessment, improvement 
This phase has the most interrelations to the traditional innovation development 
process. The specific setting of a Living Lab, focusing not on the development of 
new technology, but the application, assessment and improvement of existing 
technology (e.g. provided by particular partners) in real-life contexts, enables an 
incorporation of multiple interests resulting in a proof-of-concept. Later diffusion 
activities among regulatory bodies but also among a wider set of industry 
stakeholders can be supported by conducting impact assessment. 
4. Documentation and development of recommendation 
Deriving recommendations on the basis of former results is the main task in the 
last phase. The inclusion of scientific research, application to reallife- scenarios 
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and the assessment by users into these recommendations should therefore provide 
a basis for sustainable, well-proven and applicable solutions. 
Figure 1 illustrates the phases with the particular results and also details the third phase, 
which could encompass multiple test, assessment and improvement cycles. 
 
Alexander Kipp, Stefan Schellhammer 
445 
The alignment of particular interests and contributions among the network of 
stakeholders has already been identified as being one important issue for enabling 
standardization before. The following table therefore highlights the stakeholders of the 
proposed Living Lab setting, each having particular interests and contributing 
competencies. 
 
 
 
Academia is one key actor in the Living Labs, with its neutral and scientific basis as 
competencies. Combined with the mandate by the international institution, we believe 
that the critical task of bringing together a key community and align its interest is one 
central opportunity for the concept of Living Labs. 
4 Use of a Living Lab approach to generate CA 
Especially the first phase has been identified to be critical for establishing the momentum 
for Collective Action. The following sections discuss the application of the Living Lab 
concept in the initiation phase and the implications for the remaining two phases. 
4.1 Phase I: Initiation 
The standardization process via the coordination mechanism of a consortium requires 
actors that bring together the participants of the consortium. This process previously 
termed “initiation phase” is a necessary prerequisite to set a standardization process on 
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track. As pointed out before this phase requires two roles which have to be assumed by 
the actors. However even though an initiator might be motivated the actors may restrain 
from joining the consortium and adopt a free-rider position. This seems to be likely in 
case of dubious benefits but clear costs of participation. Furthermore the composition and 
focus of the consortium may prevent actors from joining. In this regard the initiator (in 
terms of a governmental/ intergovernmental institution) and also the designer (in terms of 
academia) play a crucial role in convincing the respective actor of his neutrality and 
mediating qualities which account for the ability to balance different interests and power 
disequilibria among the participants. 
In the case of anti-counterfeiting initiatives actors from all stages of the supply chain and 
different legal frameworks have to be brought together. This results in a high degree of 
heterogeneity among the actors. In such a consortium the multi-national, multi-billion 
manufacturer has to collaborate with the pharmacist from the next door. Thus we have to 
attribute this kind of consortium a high degree of heterogeneity not only in terms of 
money or power but in their interests regarding the outcome as well. 
A Living Lab as we introduced in the previous section has several characteristics that 
may facilitate the initiation of a standardization process.  
First of all a Living Lab is situated in the first phase of a standardization process and thus 
has also implications for the latter stages. Typical Living Labs are funded by the EU. 
This supranational governmental body provides financial funding for setting up Living 
Labs. The objectives of this funding authority are to foster the competitiveness of 
European research and industry. At the same time it expects recommendations for future 
legislative acts and the political agenda. Universities or academic institutions are 
competing on these funds by proposing projects. As projects are carried out under the 
aegis of the proposing academic institution we will focus on their role as an initiator in 
the standardization process. Despite being funded the academic institution 
is interested in the research part in the Living Lab. By designing and settingup the 
concrete Living Lab it assumes the role of an initiator. Several means are at its disposal 
to persuade industry members to join the Living Lab. First and foremost, an academic 
institution is commonly perceived as being a neutral actor that is neither politically nor 
economically biased. This neutrality is especially helpful in case of power imbalances 
among the future participants. Second, through the involvement of an academic 
institution objective and scientifically grounded results are to be expected as an outcome. 
The initiator of a Living Lab tries to bring technology providers, industrial users as well 
as users from governmental institutions together. The incentives for each of these may be 
different. The analysis and alignment of the particular interests is thus a critical task for 
the neutral academic initiator. The technology provider expects to achieve a proof-of-
concept of his technology. Furthermore the LL may serve as a forum to raise attention for 
a particular technology and discuss and test needed improvements in situ. The industrial 
users can test the application of technology and cooperation mediated by technology with 
partners (e.g. customs, other companies). As this is done in a controlled environment 
with a limited scope it has only limited impact on regular business. In this regard it 
represents a low-risk test environment (laboratory) but with results that are close to 
reality (living).  
The outcome of a Living Lab is a “pre-standard concept”. In most cases it cannot be 
directly transformed into an actual de-jure standard nor can it be marketed as a de-facto 
standard. This limitation is due to the limited scope in terms of involved stakeholders, 
products and processes that have been analyzed. This analysis and the results of the 
proof-of-concept are input for later phases of a standardization process. The major 
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achievement however is to bring actors together in order to experiment on grand-scale 
solutions in a comprehensive manner. Scale and comprehensiveness of such a proof-
ofconcept are the major assets of Living Labs in contrast to market-driven initiatives. 
Furthermore Living Labs are a vehicle to enable the actors to engage in technologies and 
initiatives that may not provide direct economic benefits. Therefore they are a promising 
means for governments to address the scarcity of public goods deemed beneficial for 
society but which are not provided by the market. 
4.2 Phase II-III: Development and Diffusion 
Starting with a proof-of-concept, which has been tested in a real-life context and a pre-
standard, which already involves multiple requirements and interests should facilitate 
phases II and III of the standardization process. The conflicts in the development phase 
are often based on missing interests of single stakeholders. By already integrating 
multiple stakeholders in the former phase and conducting impact assessment from 
multiple perspectives, we assume that this potential threat can be lowered significantly. 
In addition to the second phase, the proof-of-concept elaborated in the Living Lab can 
also enable the diffusion among the network. The decision, if an innovative technology 
or standard is adopted by one or respectively multiple parties relies, amongst other 
factors, on the applicability and sustainability of the standard. In contrast to a standard 
based on pure scientific and conceptual work, this standard has already proofed in a real-
context. In terms of network externalities, there exists already the core group of adopters 
(the Living Lab community), which might serve as the required initial point or 
„momentum‟ to facilitate the industry wide diffusion, e.g. by incorporating their 
suppliers/customers etc. 
4.3 Standardization and Drug Counterfeiting 
The inherent challenges of drug counterfeiting discussed in chapter 2 illustrated the 
complexity of the problem: Bringing multiple stakeholders together, facing a highly 
explosive issue both for industry and politics, developing standards among different 
stages of a highly branched supply chain, and incorporation of national and international 
regulatory contexts. At the same time, it makes sense to tackle the issue before the 
general necessity is discussed in the media, e.g. by creating a scandal as a consequence of 
(more) serious incidents of counterfeited drugs. Overcoming the inherent barriers of these 
challenges in the process of standardization using a Living Lab as a research environment 
seems to be a promising solution: 
From the technological perspective, multiple solutions like RFID, barcodes, tracking and 
tracing systems etc. are available. Although they are often developed for different 
contexts or tackling only very specific problems, Living Labs can be used to integrate 
existing different solutions or apply them in new contexts. Also the test, application and 
improvement in real-life context are important parts of a Living Lab with the aim to 
present a proof-of-concept. Based on this proof-of-concept, recommendations for 
regulation can be derived, but also concrete impact assessments can be conducted as 
further steps of a successful introduction of standards. 
From the organizational perspective, the multiplicity of stakeholders and the alignment of 
interests might be an obstacle for successful standardization efforts. Although awareness 
among public and private stakeholders exists, establishing an active collaboration often 
requires further efforts. In this sense Living Labs could be used as a framework to lower 
the financial and organizational barriers of collaboration. Being funded by a public 
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institution and designed/organized by an academic institution the formation of 
stakeholder group might be facilitated. 
The third challenge for standardization activities regarding the problem of counterfeiting 
is the potential discussion in the media and the loose of trust in the industry (esp. when 
the problem is discussed but no solution or at least a potential solution is presented at the 
same time). Living Labs could be used as some kind of real-life testing and developing 
environment, but at the same time not being discussed that prominently in the media as 
they are still limited to this (project) context. 
By assessing the impact of solutions, not only from a financial but also from an 
organizational perspective (e.g. in terms of social impact, strategic impact etc.) also the 
diffusion of standards might be facilitated. Facing at least some of the challenges of drug 
counterfeiting, we believe that concept of a Living Lab could facilitate the 
standardization process significantly. 
5 Conclusions 
The counterfeiting of pharmaceuticals presents a rising problem for several stakeholders. 
Ranging from being life-threatening for patients, over loss of trust against the medical 
system up to huge economic risks, the potential threat for multiple stakeholders is 
significant. Due to the nature of the problem, counterfeiting is not limited to a 
geographical region, does not end at national boundaries or is limited to certain types of 
pharmaceuticals. The complexity of the problem implies multiple challenges, e.g. how to 
enable coordinated action among different stakeholders with different interests, acting in 
different organizational and regulative environments etc. A number of initiatives are 
already in place, but none of them incorporates a coordinated and supply-chain-wide 
approach. The development of standards should therefore be the first step towards 
increased transparency along the supply chain to face the counterfeiting problem. 
Standardization processes can be distinguished in three phases: Initiation, development 
and diffusion. Each of the phases contains particular challenges, which have to be 
overcome to enable the whole process. By presenting the concept of Living Labs, 
especially the conflicts of phase I (initiation) should be tackled in a structured way. 
Academia as an economically and politically neutral actor could play the role of a 
mediator between multiple stakeholders from different sectors to align their interests and 
also ease the collaboration. Also phases II and III benefit from the concept of Living 
Labs. As the typical result of a Living Lab is a proof-of-concept and first 
recommendations for a pre-standard, the development of the real standard is supported. 
Furthermore, the diffusion among the industry is facilitated: On the one hand, the 
technology has already proven in real-life context and it also has been assessed. On this 
basis the adoption decision among a wider community could be influenced. On the other 
hand, the existing Living Lab community could serve as a nucleus for network/ industry-
wide diffusion. 
The concept of Living Labs has been applied in multiple contexts, especially for driving 
technological innovation. Actively enabling standardization activities is an innovative 
application context and has therefore proven to work in real life. Future research in this 
field can therefore be related to case studies of particular Living Labs. Further detailed 
knowledge is needed concerning the concept of Living Labs entailing its roles and 
phases. 
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